HUE030796T2 - Humán méhnyaki õssejtpopuláció és alkalmazásai - Google Patents
Humán méhnyaki õssejtpopuláció és alkalmazásai Download PDFInfo
- Publication number
- HUE030796T2 HUE030796T2 HUE13156348A HUE13156348A HUE030796T2 HU E030796 T2 HUE030796 T2 HU E030796T2 HU E13156348 A HUE13156348 A HU E13156348A HU E13156348 A HUE13156348 A HU E13156348A HU E030796 T2 HUE030796 T2 HU E030796T2
- Authority
- HU
- Hungary
- Prior art keywords
- cells
- cell
- hucescs
- conditioned medium
- cancer
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 85
- 241000282414 Homo sapiens Species 0.000 title description 37
- 210000004027 cell Anatomy 0.000 claims description 390
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 210000004556 brain Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000013351 cheese Nutrition 0.000 claims 2
- 241000218236 Cannabis Species 0.000 claims 1
- 101150079116 MT-CO1 gene Proteins 0.000 claims 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims 1
- 240000000851 Vaccinium corymbosum Species 0.000 claims 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims 1
- 229940030850 avar Drugs 0.000 claims 1
- 235000021014 blueberries Nutrition 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 238000009940 knitting Methods 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 239000003636 conditioned culture medium Substances 0.000 description 170
- 239000012091 fetal bovine serum Substances 0.000 description 61
- 238000000034 method Methods 0.000 description 57
- 239000002609 medium Substances 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 50
- 206010028980 Neoplasm Diseases 0.000 description 42
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 38
- 230000035755 proliferation Effects 0.000 description 37
- 210000003679 cervix uteri Anatomy 0.000 description 36
- 239000008194 pharmaceutical composition Substances 0.000 description 30
- 230000004069 differentiation Effects 0.000 description 28
- 238000011282 treatment Methods 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 21
- 230000012010 growth Effects 0.000 description 20
- 230000004663 cell proliferation Effects 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 19
- 230000006907 apoptotic process Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 102000006354 HLA-DR Antigens Human genes 0.000 description 16
- 108010058597 HLA-DR Antigens Proteins 0.000 description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 16
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 16
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 16
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 16
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 16
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 16
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 16
- 102100040120 Prominin-1 Human genes 0.000 description 16
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 16
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 102100022464 5'-nucleotidase Human genes 0.000 description 15
- 102100032912 CD44 antigen Human genes 0.000 description 15
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 15
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 15
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 15
- 102100025304 Integrin beta-1 Human genes 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 101710087047 Cytoskeleton-associated protein 4 Proteins 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 14
- 102100037241 Endoglin Human genes 0.000 description 14
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 14
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 14
- 102100027881 Tumor protein 63 Human genes 0.000 description 14
- 101710140697 Tumor protein 63 Proteins 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 102000000905 Cadherin Human genes 0.000 description 12
- 108050007957 Cadherin Proteins 0.000 description 12
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 12
- -1 TRA1-81 Proteins 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000004299 exfoliation Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 12
- 102000015735 Beta-catenin Human genes 0.000 description 11
- 108060000903 Beta-catenin Proteins 0.000 description 11
- 102100036912 Desmin Human genes 0.000 description 11
- 108010044052 Desmin Proteins 0.000 description 11
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 11
- 102000013127 Vimentin Human genes 0.000 description 11
- 108010065472 Vimentin Proteins 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 210000005045 desmin Anatomy 0.000 description 11
- 208000027866 inflammatory disease Diseases 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 210000005048 vimentin Anatomy 0.000 description 11
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 10
- 208000035473 Communicable disease Diseases 0.000 description 10
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 10
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000001173 tumoral effect Effects 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 9
- 102100022338 Integrin alpha-M Human genes 0.000 description 9
- 102000011782 Keratins Human genes 0.000 description 9
- 108010076876 Keratins Proteins 0.000 description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 9
- 239000002771 cell marker Substances 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 108010082117 matrigel Proteins 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 108010062580 Concanavalin A Proteins 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 244000000010 microbial pathogen Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 229960004857 mitomycin Drugs 0.000 description 7
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108090000672 Annexin A5 Proteins 0.000 description 6
- 102000004121 Annexin A5 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 102100029855 Caspase-3 Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000003365 immunocytochemistry Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108010058546 Cyclin D1 Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 5
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 210000003756 cervix mucus Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100001221 nontumorigenic Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- QCUPYFTWJOZAOB-HWKANZROSA-N (e)-n-carbamoyl-2-ethylbut-2-enamide Chemical compound CC\C(=C/C)C(=O)NC(N)=O QCUPYFTWJOZAOB-HWKANZROSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010068192 Cyclin A Proteins 0.000 description 2
- 102000002427 Cyclin B Human genes 0.000 description 2
- 108010068150 Cyclin B Proteins 0.000 description 2
- 102100025191 Cyclin-A2 Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100039328 Endoplasmin Human genes 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000812663 Homo sapiens Endoplasmin Proteins 0.000 description 2
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
- 101000689394 Homo sapiens Phospholipid scramblase 4 Proteins 0.000 description 2
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101001067395 Mus musculus Phospholipid scramblase 1 Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 208000003076 Osteolysis Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000034615 apoptosis-related disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003783 cell cycle assay Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 239000001046 green dye Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000006448 Buruli Ulcer Diseases 0.000 description 1
- 208000023081 Buruli ulcer disease Diseases 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027249 Meningitis meningococcal Diseases 0.000 description 1
- 201000010924 Meningococcal meningitis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027407 Mesothelioma malignant Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010066289 Mycobacterium ulcerans infection Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 101150037203 Sox2 gene Proteins 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009674 basal proliferation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000004677 childhood cerebellar astrocytic neoplasm Diseases 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000018981 granulocyte chemotaxis Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000024169 negative regulation of monocyte differentiation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 201000009825 uterine corpus cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/03—Coculture with; Conditioned medium produced by non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (1)
- ' iktPtgXdttdk ί: !a?~ ΐiiísörés Afpayakl AotanUUdUs OssAjtAk iaalAlps«Pa : ssaigóld addsayr, às!dtÿ á kiáAatkasdkat fSjjlsXlí! SPsgsfksp; (áj Pgy SPjtspsssyaapis oUU u sáss a Aépnyskj: síavat sät, aástyat a skêOsypk à pf»I Xselajáva ; «yarnakt (dj a ssjtek k; nyarasa sa aalitAtt tajss.iossganaiAPdt. U ) Λ a as! kPa Pt sajkák U;-nos i nsa egy angfs-tala sa Itt anyásttd käpfgOgss at oLyao kára.· tanyák kötőt ; . aast y* t taka* a va tassik a vájták Siaparodisdí: , As (dj a pas; tdpapps rannyaki payapshpSipjiS: assajuk piyp yppksfppj •adat a jkfppydks aatasshiisdU:;.· asssjîsk e.tpra s sail jak ;.; dDs9> a 04 S, £0/.1., £0185 fs à s qps, fs sas «xprsysyp tjdk a éOijyj. fais y akA-aa. rpas-ft, popáj cOOf as cOXi sajt kfnkaaàkalp 1 fs X, igánypníS Stásifti sakisaaiy .shal ás (a) Usés asgéSns jUglpijp 4 ffsyáxnyák apsiíspsIkiiS kissaggsapa;: iája·:, 3. : As is vagy 2. igésypsaf ssarinti Aódssar, aPtsI ás ásóiéit Pssajt.sk tsvddoé: Cáj gag Pas; ágálják p fifápááa^ ;: it akarat la (éKAOXAO j ,, siti. ék: 14 és So>· .. y Sál Osa rkarakAt,, ás (pj Pép; öppíUpssPljak s köv-Unstöknél é i.tó ··: sons;'· í Pöl kivé Us ét at t Ugat áss agy sajt aaaká>A ; datai!,, nk!xo> hhKvI, O-kasas in : pPO és UkPddPriA, 4. A 3, igénypont SSSAiSt:! ssddsaaa ;. alóli. ás Pásajtak tssvádaá ä kfaatkasokat sídtátjéki (áj 24 éránként 0,4· tál 3,S rygkssidéödás;g Un'jadö p;vú ; tonik ias arány a t ápkdtagPan, (P) fíOraósiasst-skárd Asafaisgla.. (aj taps UPS ti: Aajtpasssásspa: UiaUaPö sióét ; kaaádáfspái (d) ágyáét aga ;kUays3as>a; és agy stnnsxi.rfshnt tassxna tppspdsrs mid kapassdg, (a) andodaoast is, dktddarssdjls vagy na tsdaraál i s sajt vasat sAsúMgt áá gk ä la Sa stat data s «g. (fj nas; ty-ésrigon kapa ai tps ég/yagy i'g) géasoi iftiASotâsaaa vasa kágasság, 5. as t s . tgésypaatak Agyiks Atsaàsti addst®?p a h si a aénnyaPi stdvat agy ;nUss aéPnya;·;. ssavataP, y lányosán Pools sàdpyski s tova!. is. A ssaheyaC erío;. ;a< Λ ;s révén rsysri i xsl ils: : æ.èfeî?y\akl safeyaà: ?'-r: i ist ;; easi taaax'ôs arte; a ϊΦη! .:.·:; téferyaCi fsséjtek rivyaréibrt; arCri ;.· PéfestyaCi Si«aée:ehissái:is ësssj tar aspra;:-ráérjék :; Cbié,, CCkU.,. CD H. CCS«C és s: Hivő, as ara ssprasssát. jak s CDit?., CDHily Hi.H-DC., TCAl-si, GMé , O.H4 M CDâl sajt sfefeHerakfl- 7. agy Ázsiáit:, q§® tpsioeos asexehéMskélls .BéferyaCi asäfjH aeelyet y sséfenyak as-íai iá··: iajévai avarnak, shoi 5:? fefetiieti raj·. : C4) Ckpre.sAí:iija s: Cb®., épié., CO?:·:, CpS® CPifp, viééééHH tstökefaitp K·· C4, DctA si·-:. s Sas-s sali: aarkàreCai .< -H. Çfej Péé èkpsissss;ïI3a: à U.®./, Coll® HLi:-Pif; Tkél-ki, C.047 : CQ34 es CPP! :séjt esréarekei f alfehyätsb élyiifihfëo scs éspméstil a kbyetkesőfehii ailé ésbbörtfeai k I vais; sétái t legaihbp egy sajt: sarkért s :á«.?síis5;{: sktip HHF3S;<. p: >·’-¾t ¢-:r·:· r-. pS3 ék &-Cypher ta. b. A 7. igéaypissi sseriati íróiéi!. sétaj; . éhei a sejt CSVsbfeé S köeetkékökéí: séiíatjá' isti 74 prénsénf 0,4-17] jp soigkeuékPPésig tér jade pral Ha;® iPs séahy a iarKíregaea, ( bj fibs'ehis:;·;·:i ···:::reéi fia rfelégia. {e) iegtéUsbb .Hi, a Hiayéser 78 feajigasppilsrd k Lier jetié stkpil ikahiátihisS:, (fej egyrétegű apvekedásre és agy sstífesztriiihaa tértieé tapsbisaa veié képesség., (a) séspagá«, öéitaegMí byufeáíis vagy sétppitp aajtvoégl §yak:J.étí segkölfeafeösfefehetfeségs <:f) rec tusor-J gén kapspitM és/vagy Cg) geaaok :lst:refeö®áaéra yaiss kégassag, k 4 vagy f. igérypaet ::<»?'.! a! i j.relisi basait, sehol a sajt: agy e-slesbéi, ejenypsap aabarbai : lég eioayfesebbea agy ám- éésistayécliis fatisbah ívva aébferbfel onP aarsk. Hi. A 7-fe. ja:abyfebgy;gfe pgrpaiyikc sgabifeti iSöialt őssáltat CaHai»ar;i sai!papul ke I.o, Ili. :A Ctybikaafelat sipgáböp -ifegXéXp ssbäsaebrel Csabit 'ksaficibnaii kpAsgi (a) A ?··!>. igénygoeéek bársaiyiCa saarirti italéit őssejt vágy a la. igenypnni síáaiati sejt grossi Pcié Xhk yPfecXPj is > és Ibi a sajtak aitavslstiiss a taayéazté: CSaegfeöiU il. A 7-7. Igasyparstak bsrsaXyjke ssssHri:! iyaipit össajtat., a 1C, igéaypoat sasrsati se jtbapblicipt vagy S IS . igény sasa; sserirti kansn;: iasiá.: t aaraget taris; inas-si gyagySáer'ésáÍíti kèsMlsréaÿj. eSiaairit agy gyfegysnamsaatiiag alfíjgaíiható feardöáésayssg é:s/sfégy ad yn/Hv.. : ÍS. Ά 7--9, igaoypon» ok >···.: tysrioli itaigit Ssseitj a )8. iggaygikst kkkstinta ra ji papai avis yggy a 71- lgëêygônt: gäsrifiti kpgdietgnPlt kJsogä vagy a .US. i.;yp';yp;>n: ;. rer in ei. gyógy :uerk:;.a8: ; kP;r.?1 retry, gyógyszerként törtgso slkPisPigakPS, 1:4. & V--8. ige: ;y porroe rá:-<-<· 1 yikí- száriéit italait ésse j ; ; a 19, igéáypont ssórirtl kéjtρρρρlâçiéj a 11, igényperí szerinti kondin ion;, ; v kareg, vagy :a 11, tgénofgisai ;; -ariaU gÿygysaerésgeti kysgltyyhy, rykj gyűliadlros i> öregségek, aoloir-oea igkiggSggék, krsnikrr paislégiak ysgy Orte-a aatygsjggk kötelese vagy .sktgsXésssa soysíV tgrtgpé glkalsíagásra:, is. A 7-8, IgopygentSk kárkélyiks: ikkerintt iaeikstt ésseja, s .18. igényper; szekints vritprpnliv: ié, a 1,1, Igánypöáí :;gâri«ï:i koobitisnait kiiseg vagy S 18, igesypest kaerjdti gyógy;..·: sx eszei 5 kyktitteny ä: 14. Igénypont stsnlnti :alk0!#3kiknkt à iissorseitek peaiiisrieiSja és/yàgÿ sebastiPziss, «: sönsoítas aiflerenoiiládás.i a perifériás vár ro:K:nok loan la kelték grOlifgèscigys ÿâgy g gatègin glkróotgaítig-ays eavekediss Os/vagy rapizkieiPj» g àriPiávo) vagy tsdkkebiëkëysi vagy a tldiörsejték igSpSotiSgnsk fököaásaygl vagy ingokallsätal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13156348.8A EP2770050B1 (en) | 2013-02-22 | 2013-02-22 | Human uterine cervical stem cell population and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE030796T2 true HUE030796T2 (hu) | 2017-06-28 |
Family
ID=47749687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13156348A HUE030796T2 (hu) | 2013-02-22 | 2013-02-22 | Humán méhnyaki õssejtpopuláció és alkalmazásai |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20160000835A1 (hu) |
| EP (1) | EP2770050B1 (hu) |
| JP (1) | JP6453771B2 (hu) |
| KR (1) | KR102175493B1 (hu) |
| CN (1) | CN105008520B (hu) |
| AU (1) | AU2014220647B2 (hu) |
| BR (1) | BR112015020001A2 (hu) |
| CA (1) | CA2901505C (hu) |
| CY (1) | CY1118704T1 (hu) |
| DK (1) | DK2770050T3 (hu) |
| ES (1) | ES2615824T3 (hu) |
| HK (1) | HK1214300A1 (hu) |
| HR (1) | HRP20170216T1 (hu) |
| HU (1) | HUE030796T2 (hu) |
| IL (1) | IL240573B (hu) |
| LT (1) | LT2770050T (hu) |
| MX (1) | MX2015010708A (hu) |
| NZ (1) | NZ712583A (hu) |
| PL (1) | PL2770050T3 (hu) |
| PT (1) | PT2770050T (hu) |
| RS (1) | RS55656B1 (hu) |
| RU (1) | RU2679500C2 (hu) |
| SI (1) | SI2770050T1 (hu) |
| SM (1) | SMT201700114B (hu) |
| WO (1) | WO2014128291A1 (hu) |
| ZA (1) | ZA201506818B (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107208049A (zh) * | 2014-09-18 | 2017-09-26 | 财团法人卫生研究院 | 祖细胞、其制备方法及其应用 |
| KR20180012223A (ko) * | 2016-07-25 | 2018-02-05 | 고려대학교 산학협력단 | 자궁 유래 성체줄기세포 분리 및 제조 방법 |
| GB2571668B (en) * | 2017-02-16 | 2023-02-22 | Oct Therapies And Res Private Limited | Stem cell conditioned media for clinical and cosmetic applications |
| CN108865973A (zh) * | 2018-06-20 | 2018-11-23 | 广西医科大学第附属医院 | Sd大鼠胃窦间质细胞的分离和培养方法 |
| WO2021226373A2 (en) * | 2020-05-08 | 2021-11-11 | Gallant Pet, Inc. | Uterine-derived regenerative cell compositions and uses thereof |
| CN112057471B (zh) * | 2020-09-11 | 2023-12-22 | 复旦大学附属妇产科医院 | 间充质干细胞的制药用途 |
| CN112618712A (zh) * | 2021-01-21 | 2021-04-09 | 武汉轻工大学 | 一种含波形蛋白的佐剂及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011042547A1 (en) * | 2009-10-08 | 2011-04-14 | Projech Science To Technology, S.L. | Myometrial-derived mesenchymal stem cells and uses thereof |
| CN102229911B (zh) * | 2011-06-08 | 2013-09-18 | 山西医科大学 | Sca-1+/CD34－子宫干细胞及其分离方法 |
| RU2481585C1 (ru) * | 2011-11-09 | 2013-05-10 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздравсоцразвития России) | Способ дифференциальной диагностики лейомиосарком и пролиферирующих (клеточных) лейомиом матки |
-
2013
- 2013-02-22 PL PL13156348T patent/PL2770050T3/pl unknown
- 2013-02-22 PT PT131563488T patent/PT2770050T/pt unknown
- 2013-02-22 SI SI201330528A patent/SI2770050T1/sl unknown
- 2013-02-22 ES ES13156348.8T patent/ES2615824T3/es active Active
- 2013-02-22 LT LTEP13156348.8T patent/LT2770050T/lt unknown
- 2013-02-22 DK DK13156348.8T patent/DK2770050T3/en active
- 2013-02-22 HU HUE13156348A patent/HUE030796T2/hu unknown
- 2013-02-22 EP EP13156348.8A patent/EP2770050B1/en active Active
- 2013-02-22 RS RS20170164A patent/RS55656B1/sr unknown
-
2014
- 2014-02-24 AU AU2014220647A patent/AU2014220647B2/en active Active
- 2014-02-24 US US14/769,563 patent/US20160000835A1/en not_active Abandoned
- 2014-02-24 KR KR1020157025694A patent/KR102175493B1/ko active IP Right Grant
- 2014-02-24 WO PCT/EP2014/053508 patent/WO2014128291A1/en active Application Filing
- 2014-02-24 BR BR112015020001-0A patent/BR112015020001A2/pt not_active Application Discontinuation
- 2014-02-24 JP JP2015558481A patent/JP6453771B2/ja active Active
- 2014-02-24 CN CN201480010063.3A patent/CN105008520B/zh active Active
- 2014-02-24 RU RU2015139970A patent/RU2679500C2/ru active
- 2014-02-24 NZ NZ712583A patent/NZ712583A/en unknown
- 2014-02-24 CA CA2901505A patent/CA2901505C/en active Active
- 2014-02-24 MX MX2015010708A patent/MX2015010708A/es unknown
-
2015
- 2015-08-13 IL IL240573A patent/IL240573B/en active IP Right Grant
- 2015-09-15 ZA ZA2015/06818A patent/ZA201506818B/en unknown
-
2016
- 2016-02-25 HK HK16102201.3A patent/HK1214300A1/zh unknown
-
2017
- 2017-02-09 HR HRP20170216TT patent/HRP20170216T1/hr unknown
- 2017-02-15 CY CY20171100206T patent/CY1118704T1/el unknown
- 2017-02-21 SM SM201700114T patent/SMT201700114B/it unknown
-
2021
- 2021-04-09 US US17/227,252 patent/US20210299184A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2770050T3 (en) | Human cervical stem cell population and uses thereof | |
| Shiota et al. | Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties | |
| Di Rocco et al. | Myogenic potential of adipose-tissue-derived cells | |
| Nikoo et al. | Effect of menstrual blood‐derived stromal stem cells on proliferative capacity of peripheral blood mononuclear cells in allogeneic mixed lymphocyte reaction | |
| KR20180100250A (ko) | 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료 | |
| Montemurro et al. | Angiogenic and anti-inflammatory properties of mesenchymal stem cells from cord blood: soluble factors and extracellular vesicles for cell regeneration | |
| Wu et al. | Serum-free media and the immunoregulatory properties of mesenchymal stem cells in vivo and in vitro | |
| Fossett et al. | The effects of ageing on proliferation potential, differentiation potential and cell surface characterisation of human mesenchymal stem cells | |
| Kellner et al. | Differential properties of human stromal cells from bone marrow, adipose, liver and cardiac tissues | |
| Yew et al. | Efficient expansion of mesenchymal stem cells from mouse bone marrow under hypoxic conditions | |
| Klemmt et al. | Murine amniotic fluid stem cells contribute mesenchymal but not epithelial components to reconstituted mammary ducts | |
| US20120177618A1 (en) | Hematopoietic stromal progenitor cells and uses thereof | |
| Pozzobon et al. | Fetal stem cells and skeletal muscle regeneration: a therapeutic approach | |
| Jazedje et al. | Stem cells from umbilical cord blood do have myogenic potential, with and without differentiation induction in vitro | |
| Galvez et al. | An adult myometrial pluripotential precursor that promotes healing of damaged muscular tissues | |
| Bana et al. | A comparative study to evaluate myogenic differentiation potential of human chorion versus umbilical cord blood-derived mesenchymal stem cells | |
| Zani et al. | Stem cell therapy as an option for pediatric surgical conditions | |
| TWI535848B (zh) | 包含眼窩脂肪衍生之幹細胞（ｏｆｓｃ）之細胞群及彼等之分離與應用 | |
| US20190105353A1 (en) | Somatic stem cells for treating bone defects | |
| Gong et al. | Human umbilical cord blood mesenchymal stem cells conditioned media inhibits hypoxia-induced apoptosis in H9c2 cells by activation of the survival protein Akt | |
| JP6777323B2 (ja) | 毛細血管由来幹細胞、その用途、及び、その製造方法 | |
| Ahmed et al. | Characterization and differentiation potential of bone marrow-derived mesenchymal stem cells of male albino rats | |
| Al-Shafie et al. | A cost-saving technique of human somatic liver stem cells isolation for ex vivo propagation and characterization | |
| Meng et al. | Adult Stem Cells: Adult Skeletal Muscle Stem Cells |